Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

Summary

This phase I trial is studying the side effects and best dose of cediranib maleate when given together with cilengitide in treating patients with progressive or recurrent glioblastoma. Cediranib maleate and cilengitide may stop the growth of tumor cells by blocking blood flow to the tumor. Giving cediranib maleate together with cilengitide may kill more tumor cells.

Timeline

Start

2010-03

Primary completion

2012-05

Completion

2014-02

Drugs

Indications